Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
1.370
-0.010 (-0.72%)
Oct 6, 2025, 4:00 PM EDT - Market closed

Company Description

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States.

It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet’s disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis.

Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola.

The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009.

Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Soligenix, Inc.
Soligenix logo
CountryUnited States
Founded1987
IPO DateJun 15, 1987
IndustryBiotechnology
SectorHealthcare
Employees16
CEOChristopher Schaber

Contact Details

Address:
29 Emmons Drive, Suite B-10
Princeton, New Jersey 08540
United States
Phone609 538 8200
Websitesoligenix.com

Stock Details

Ticker SymbolSNGX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000812796
CUSIP Number834223604
ISIN NumberUS8342236044
Employer ID41-1505029
SIC Code2834

Key Executives

NamePosition
Dr. Christopher J. Schaber Ph.D.Chairman of the Board of Directors, Chief Executive Officer and President
Dr. Oreola Donini Ph.D.Senior Vice President and Chief Scientific Officer

Latest SEC Filings

DateTypeTitle
Oct 1, 2025SCHEDULE 13GFiling
Sep 29, 20258-KCurrent Report
Sep 26, 2025424B4Prospectus
Sep 25, 2025EFFECTNotice of Effectiveness
Sep 19, 2025S-1General form for registration of securities under the Securities Act of 1933
Aug 27, 2025DRS[Cover] Draft Registration Statement
Aug 18, 20258-KCurrent Report
Aug 15, 2025424B3Prospectus
Aug 15, 20258-KCurrent Report
Aug 15, 2025424B3Prospectus